Tomas Hala

4.7k citations
9 papers · 682 · 1 hit paper · h-index 7

Impact in

  • Surgery top 5%
    • Lipoproteins and Cardiovascular Health
    • Biosimilars and Bioanalytical Methods
    • Atherosclerosis and Cardiovascular Diseases

Papers in

Tomas Hala

9 papers receiving 669 citations

Tomas Hala's Hit Papers

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia 2014 · 560 citations
5600+4+8Years since publication100200300400500

Peers

Tomas Hala
Comparison fields: 5 of 50
  • Surgery 466
  • Immunology 153
  • Economics and Econometrics 145
  • Endocrinology, Diabetes and Metabolism 81
  • Cancer Research 57
Replace Ricardo E. Dent-Acosta with:
Ricardo E. Dent-Acosta United States
Zsolt Talloczy United States
Mary Elliott‐Davey United States
P. Pfister France
Arjen J. Cupido Netherlands
Thomas Hucko Germany
O. Afanasieva Russia
Elise F. Villard France
Robert A. Hegele United States
Amy Damask United States
Tomas Hala relative to Ricardo E. Dent-Acosta United States Ricardo E. Dent-Acosta's profile →
Citations per field
00.5×4.8×
Ricardo E. Dent-Acosta · 1×
Citations per year

Countries citing papers authored by Tomas Hala

Since Specialization
Citations

This map shows the geographic impact of Tomas Hala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomas Hala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomas Hala more than expected).

Fields of papers citing papers by Tomas Hala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomas Hala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomas Hala. The network helps show where Tomas Hala may publish in the future.

Co-authors

The 25 scholars most cited alongside Tomas Hala, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tomas Hala Line = papers co-authored together Tomas Hala links everyone, so they are left out of the graph.

All Works

9 of 9 papers shown
#Work
1
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Hit paper breakdown →
2014560
2 201845
3 201920
4 200617
5 202015
6 200812
7 20108
8 20183
9 20242

About Tomas Hala

Tomas Hala is a scholar working on Immunology, Orthopedics and Sports Medicine, Rheumatology, Surgery and Pediatrics, Perinatology and Child Health, having authored 9 papers that have together received 682 indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (4 papers), Bone health and osteoporosis research (3 papers), Spondyloarthritis Studies and Treatments (1 paper), Lipoproteins and Cardiovascular Health (1 paper), Pharmaceutical studies and practices (1 paper) and Rheumatoid Arthritis Research and Therapies (1 paper). The work is most often cited by research in Surgery (466 citations), Immunology (153 citations), Economics and Econometrics (145 citations), Endocrinology, Diabetes and Metabolism (81 citations) and Cancer Research (57 citations). Tomas Hala has collaborated with scholars based in United States, Czechia and United Kingdom. Frequent co-authors include Robert C. Scott, Kate Tsirtsonis, Maria Laura Monsalvo, Lesley Burgess, Dirk Blom, Michael Lillestol, Phillip D. Toth, Evan A. Stein, Michael A. Bolognese and Michael J. Koren. Their work appears in journals such as Maturitas, Arthritis Research & Therapy, Annals of the Rheumatic Diseases, Rheumatology and Therapy and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact